A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Palvella Therapeutics, Inc. · NCT07552077
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 6+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 15
- US sites recruiting
- 2
- Study start
- April 2026
- Record last updated
- April 27, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Being studied: PTX-022
Conditions: Angiokeratomas
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants must be 6 years or older
- Diagnosed with angiokeratoma
- Able and willing to comply with all protocol-related activities
- Willing and able to provide written informed consent
Exclusion Criteria
- Any significant concurrent condition that could adversely affect participation
- Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022
- Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities
Recruiting US locations
Cleaver Medical Group
Dawsonville, GA 30534
Site contact: Dana Anderson · 770.800.3455 · danderson@cleavermedicalgroup.com
Epiphany Dermatology
Southlake, TX 76092
Site contact: Moraima Avalos · (214) 884 - 7558 · chintan@stryderesearch.com
Study contacts (from the official record)
- Emily Cook · 267-738-6366 · emily.cook@palvellatx.com